Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | FGF23 | Q9GZV9 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533982 | 1.00 | ALOX12 (0.47) | ALOX12FGF23LMNATRPA1ATM | |
| SCHEMBL2161592 | 1.00 | ALOX12 (0.47) | ALOX12FGF23LMNATRPA1ATM | |
| Ammonia Solution, Strong SCHEMBL27921774 | 0.98 | ALOX12 (0.46) | ALOX12FGF23LMNATRPA1ATM | |
| SCHEMBL2160910 | 0.82 | FGF23 (0.53) | ALOX12FGF23LMNAHPGDMAPT | |
| SCHEMBL406151 | 0.82 | FGF23 (0.53) | ALOX12FGF23LMNAHPGDMAPT | |
| SCHEMBL406150 | 0.82 | FGF23 (0.53) | ALOX12FGF23LMNAHPGDMAPT | |
| SCHEMBL5078088 | 0.81 | ALOX12 (0.59) | ALOX12FGF23LMNATRPA1HPGD | |
| SCHEMBL17548951 | 0.81 | ALOX12 (0.59) | ALOX12FGF23LMNATRPA1HPGD | |
| SCHEMBL11042113 | 0.81 | ALOX12 (0.50) | ALOX12FGF23LMNATRPA1ATM | |
| SCHEMBL6825334 | 0.81 | ALOX12 (0.59) | ALOX12FGF23LMNATRPA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070114155-A1 | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL RAFFINAGE FRANCE (FR) | 2007-05-24 | — | — | US | claimed |
| JP-2007501701-A | — | — | 2007-02-01 | — | — | JP | claimed |
| CN-1845789-A | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL FRANCE (FR) | 2006-10-11 | — | — | CN | claimed |
| EP-1660232-A1 | HYDROTREATING AND/OR HYDROCRACKING CATALYST OF HYDROCARBONS AND PREPARATION THEREOF | Total France (FR) | 2006-05-31 | — | — | EP | claimed |
| WO-2005016518-A1 | HYDROTREATING AND/OR HYDROCRACKING CATALYST OF HYDROCARBONS AND PREPARATION THEREOF | TOTAL FRANCE (FR) | 2005-02-24 | — | — | WO | claimed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| CN-104703980-B | Belong to the orexin receptor antagonists of [adjacent double (miscellaneous) aryl] [base of 2 (double (miscellaneous) aryl) pyrrolidines 1] ketone derivatives | 埃科特莱茵药品有限公司 | 2017-09-22 | — | — | CN | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2906553-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-19 | — | — | EP | disclosed |
| CN-104703980-A | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD | 2015-06-10 | — | — | CN | disclosed |
| WO-2014057435-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-04-17 | — | — | WO | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-1660232-B1 | HYDROTREATING AND/OR HYDROCRACKING CATALYST OF HYDROCARBONS AND PREPARATION THEREOF | TOTAL RAFFINAGE MARKETING (FR) | 2009-07-22 | — | — | EP | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070114155-A1 | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL RAFFINAGE FRANCE (FR) | 2007-05-24 | — | — | US | disclosed |
| CN-1845789-A | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL FRANCE (FR) | 2006-10-11 | — | — | CN | disclosed |
| EP-1660232-A1 | HYDROTREATING AND/OR HYDROCRACKING CATALYST OF HYDROCARBONS AND PREPARATION THEREOF | Total France (FR) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016518-A1 | HYDROTREATING AND/OR HYDROCRACKING CATALYST OF HYDROCARBONS AND PREPARATION THEREOF | TOTAL FRANCE (FR) | 2005-02-24 | — | — | WO | disclosed |
| CN-1254335-A | Nicotinamide derivatives | PFIZER PROD INC (US) | 2000-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | ALOX12 1074/4885FGF23 1266/4885LMNA 3489/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | ALOX12 3710/4885FGF23 4061/4885LMNA 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.